No Data
Jazz Pharmaceuticals Reprices $2.7 Billion Outstanding Balance of Term Loan Facility
Jazz Pharmaceuticals (JAZZ) said Monday it repriced the roughly $2.7 billion outstanding balance of its term loan facility, which is expected to yield annual interest savings of about $23 million.
Express News | Jazz Pharmaceuticals Announces Successful Completion of Term Loan Repricing and Irrevocable Election of Settlement Method for the 2.000% Exchangeable Senior Notes Due 2026
BofA Securities Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Maintains Target Price $172
BofA Securities analyst Jason Gerberry maintains $Jazz Pharmaceuticals(JAZZ.US)$ with a buy rating, and maintains the target price at $172.According to TipRanks data, the analyst has a success rate
Buy Rating Upheld for Jazz Pharmaceuticals Amidst Potential for Growth and Strategic Revaluation
Express News | Jazz Pharmaceuticals to Report 2024 Second Quarter Financial Results on July 31, 2024
Jazz Pharmaceuticals' (NASDAQ:JAZZ) Earnings Trajectory Could Turn Positive as the Stock Climbs 5.5% This Past Week
As an investor its worth striving to ensure your overall portfolio beats the market average. But in any portfolio, there are likely to be some stocks that fall short of that benchmark. We regret
The Real Wojak : Do you have like a top 3-5 that you like more than all the other ones? This list is way too long
72991267 : Glad I have some $Candel Therapeutics (CADL.US)$ after my disastrous SBFM.
Rana Hasan1 : List too long